Latest News – 16 February 2026

Medicinal Product Supply

Influenza Vaccine Influvac Available in Germany with Italian Label

Chikungunya Vaccine Vimkunya with French Labelling Available Again in Germany

Annual Meeting at the Paul-Ehrlich-Institut: Effectively Countering Vaccine Supply Shortages

International

World Cancer Day – Paul-Ehrlich-Institut Strives for Safe and Innovative Cancer Treatment and Prevention

World Neglected Tropical Diseases Day: Paul-Ehrlich-Institut Actively Contributes to Global Health Through Research and Regulation

Paul-Ehrlich-Institut’s GHPP Projects Enter their Next Phases in 2026

HPV Vaccines

Boosting Awareness of HPV Vaccination: Paul-Ehrlich-Institut Supports Vaccination Concept Developed by the National Steering Committee on Vaccination and Nationwide HPV Vaccination Year Planned for 2028

#VaccineFacts

#VaccineFacts Continue Their Impact: The Paul-Ehrlich-Institut Provides Vaccine Information – Even Beyond the Digital Awareness Campaign

Medicine Safety

Pharmacovigilance Report on the Use of COVID-19 Vaccines – Status as of 31 December 2024

FAQ: What should be taken into account when using public data on reports of suspected adverse events?

Information on the Topic of Vaccination Damages

The Paul-Ehrlich-Institut is not responsible for processing applications for recognition of vaccine damages.

The Paul-Ehrlich-Institut does not have any information, figures/data on vaccine damage procedures.

Recognition procedures for vaccination damages in accordance with section 24 of the Social Code (Sozialgesetzbuch, SGB) XIV are handled exclusively by the Social Welfare Office in the federal state in whose territory the vaccination was carried out. Sections 4, 5 and 113 of the SGB XIV provide information on the competent authority, compensation for official measures and payment obligations.

Important Short Links for Your Research

• Da­ta on suspected Ad­verse Drug Re­ac­tions
  www.pei.de/adr-data
• COVID-19 safety reports:
  www.pei.de/safety-covid-19-vaccines
• COVID-19 vaccines (with link to product information):
  www.pei.de/covid-19-vaccines
• Corona FAQ (including approval and development, efficacy and safety, batch testing and antigen testing):
  www.pei.de/faq-coronavirus-en
• Explainer videos as well as recordings of press briefings:
  www.youtube.com/channel/UC0GDU8v6JtuozYQqfjJN8bg/videos

top